Inactive Instrument

News Onyx Pharmaceuticals, Inc.

Equities

US6833991093

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2013	Gilead Sciences, Inc. : Bradway's patient dealmaking brings Onyx to Amgen	RE
2013	Onyx Pharmaceuticals, Inc. : Onyx deal expected to give Amgen a big boost	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Onyx Pharmaceuticals : Amgen Receives CHMP Positive Opinions for Two New Treatment Options for Patients with Blood Cancer in Europe	15-10-01	PU
Onyx Pharmaceuticals : Amgen Submits Supplemental New Drug Application for Kyprolis® (Carflizomib) in Relapsed Multiple Myeloma	15-07-23	PU
Onyx Pharmaceuticals : Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (Carflizomib) in Patients with Relapsed and Refractory Multiple Myeloma	15-05-31	PU
Onyx Pharmaceuticals : Amgen to Advance Understanding of the Treatment of Blood Cancers at the 20th Congress of European Hematology Association (EHA)	15-05-27	PU
Onyx Pharmaceuticals : Amgen Data at ASCO 2015 Highlight Oncology Pipeline and Portfolio	15-05-13	PU
Onyx Pharmaceuticals : Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority of Kyprolis® (carfilzomib) Over Velcade® (Bortezomib) in Patients with Relapsed Multiple Myeloma	15-03-01	PU
Onyx Pharmaceuticals : Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing Authorization Application for the Treatment of Relapsed Multiple Myeloma	15-02-26	PU
Onyx Pharmaceuticals : Amgen and Onyx Announce Detailed Results from Phase 3 ASPIRE Study of Kyprolis® (carfilzomib) in Patients with Relapsed Multiple Myeloma	14-12-06	PU
Onyx Pharmaceuticals : FDA Approves BLINCYTO™ (blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia	14-12-03	PU
Onyx Pharmaceuticals : Amgen Highlights New Data in The Treatment of Blood Cancers at ASH 2014	14-11-06	PU
Onyx Pharmaceuticals : Amgen Announces Top-line Results from Phase 3 FOCUS Trail of KYPROLIS® in Patients with Relapsed and Advanced Refractory Multiple Myeloma	14-08-13	PU
Onyx Pharmaceuticals : Amgen Announces Phase 3 ASPIRE Trial of Kyprolis in Patients with Relapsed Multiple Myeloma Met Primary Endpoint	14-08-04	PU
Onyx Pharmaceuticals, Inc. : Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation	14-03-11	PU
Onyx Pharmaceuticals, Inc. : The International Myeloma Foundation Announces Partnership with Onyx Pharmaceuticals to Support Black Swan Research Initiative	13-12-06	PU
Onyx Pharmaceuticals, Inc. : U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment	13-11-22	PU
Onyx Pharmaceuticals, Inc. : Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting	13-11-07	PU
Onyx Pharmaceuticals, Inc. : Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer	13-10-01	PR
Onyx Pharmaceuticals, Inc. : Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx	13-09-18	PR
Onyx Pharmaceuticals, Inc. : Onyx Pharmaceuticals Announces Data Presentations at 2013 European Cancer Congress	13-09-17	PU
Onyx Pharmaceuticals, Inc. : Bayer’s Stivarga® (regorafenib) Tablets Approved in Europe	13-08-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Onyx Pharmaceuticals, Inc.

Equities

US6833991093

Summary

Filters